Synthetic Anticancer Vaccine Candidates: Rational Design of Antigenic Peptide Mimetics That Activate Tumor-Specific T-Cells - Archive ouverte HAL Access content directly
Journal Articles Journal of Medicinal Chemistry Year : 2007

Synthetic Anticancer Vaccine Candidates: Rational Design of Antigenic Peptide Mimetics That Activate Tumor-Specific T-Cells

(1, 2) , (2) , (3) , (4, 3) , (3, 4) , (1, 2)
1
2
3
4

Abstract

A rational design approach was followed to develop peptidomimetic analogues of a cytotoxic T-cell epitope capable of stimulating T-cell responses as strong as or stronger (heteroclytic) than those of parental antigenic peptides. The work described herein focused on structural alterations of the central amino acids of the melanoma tumor-associated antigenic peptide Melan-A/MART-1 26-35 using nonpeptidic units. A screening was first realized in silico to select altered peptides potentially capable of fitting at the interface between the major histocompatibilty complex (MHC) class-I HLA-A2 molecule and T-cell receptors (TCRs). Two compounds appeared to be high-affinity ligands to the HLA-A2 molecule and stimulated several Melan-A/MART-1 specific T-cell clones. Most remarkably, one of them even managed to amplify the response of one clone. Together, these results indicate that central TCR-contact residues of antigenic peptides can be replaced by nonpeptidic motifs without loss of binding affinity to MHC class-I molecules and T-cell triggering capacity.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03349324 , version 1 (20-09-2021)

Identifiers

Cite

Céline Douat-Casassus, Nathalie Marchand-Geneste, Elisabeth Diez, Nadine Gervois, Francine Jotereau, et al.. Synthetic Anticancer Vaccine Candidates: Rational Design of Antigenic Peptide Mimetics That Activate Tumor-Specific T-Cells. Journal of Medicinal Chemistry, 2007, 50 (7), pp.1598-1609. ⟨10.1021/jm0613368⟩. ⟨inserm-03349324⟩
11 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More